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Human papillomavirus (HPV) vaccines protect against the types of HPV that cause anogenital and 
oropharyngeal cancers (HPV 16 and 18). The quadrivalent HPV (qHPV) vaccine is also effective 
against the types of HPV that cause genital warts (HPV 6 and 11). Most vaccines prevent infections 
by generating antibodies (Abs), yet it has been unclear why some vaccines provide long-term or 
even life-long protection, while others such as the tetanus toxoid vaccine (TT), require boosters. The 
qHPV vaccine is an example of a subunit vaccine where, rather than using the pathogen in its 
entirety, only part of the pathogen is used. Subunit vaccines typically have fewer adverse reactions 
and are ideal for pathogens where use of live, attenuated or inactivated pathogens presents safety 
concerns. The qHPV vaccine is highly effective, and previous studies have shown sustained Ab 
levels up to 5 years post-vaccination and a boost in Ab responses upon re-vaccination. While this is 
consistent with HPV vaccination eliciting plasma cells (cells that secrete Abs for long periods of time) 
and memory B cells (Bmem; cells that can rapidly differentiate into Ab-secreting plasmablasts upon 
antigen re-exposure), HPV-specific Bmem had never been characterized. 
A recent Fred Hutch study, conducted in the lab of Dr. Denise Galloway in the Human Biology 
Division, and published in the journalPLOS Pathogens, sought to understand the immunological 
memory evoked by a successful vaccine in the absence of pre-existing immunity. "Our study is the 
first to characterize the memory B cells elicited by HPV vaccination. It's really just a starting point for 
understanding what immune responses make the HPV vaccine so effective", said lead author Dr. 
Erin Scherer. 
The authors first needed to develop a strategy to isolate HPV-specific Bmem. To achieve this, the 
investigators first purified B cells from peripheral blood samples obtained from 12 qHPV vaccine 
recipients at one month post-vaccination. They then used a flow cytometry-based method to 
discriminate HPV 16-specific Bmem. A particular combination of cell surface markers was used to 
identify classic Bmem (CD27+, IgD–). To distinguish HPV 16-specific Bmem, fluorescently labeled 
HPV16 pseudoviruses (psV) served to label antigen receptors on the surface of HPV 16-specific 
Bmem. These psV are composed of two capsid proteins, L1 and L2, where L1 is the antigen in the 
qHPV vaccine. Fluorescently labeled bovine papillomavirus (BPV) psV were included as a control. 
Importantly, HPV16+ Bmem, but not BPV+ Bmem, were detected. The authors then cloned Abs from 
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singly sorted HPV16+ Bmem and found that these were predominantly IgG in nature, and exhibited 
moderate levels of somatic hypermutaton, comparable to that observed for Abs cloned from healthy 
donors or TT vaccinees, rather than the high levels observed for certain broadly-neutralizing HIV-1 
Abs. Finally, the authors demonstrated that 8 out of 12 Abs cloned from single HPV16+ Bmem 
potently neutralized HPV16 psV. Collectively, these data show that the authors’ labeling method 
selectively identified antigen-specific HPV16+ Bmem and is consistent with the emerging view that 
somatic hypermutation is not a prerequisite for potent neutralizing activity by Abs. 
"We hope to use such information as a benchmark for vaccine development against other infectious 
agents. We will also use this strategy to evaluate whether fewer doses of the expensive HPV 
vaccine generates comparable memory responses. Such considerations are particularly relevant to 
the distribution of this vaccine in developing countries." , explained Dr. Scherer. 
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In order to characterize the immunological memory generated by the qHPV 
vaccine, blood was collected from girls (aged 9-13 years) and young 
women (aged 18-26 years) one month after receiving their final vaccine 
dose. HPV16-specific memory B cells were isolated from these samples 
using flow cytometry methods, and full-length antibodies were cloned from 
these cells. These antibodies were then characterized for their sequence 
characteristics and anti-viral activity. 
 
